Voluntary nationwide recall: Vancomycin (Amneal - March)
Apr. 2024Pharmacy Updates
Amneal Pharmaceuticals, LLC is recalling four lots of Vancomycin Hydrochloride for Oral Solution, USP, 250 mg/5 mL. Vancomycin is used for treatment of certain bacterial infections.
This drug is being recalled because some bottles may have been overfilled. This may cause a higher dose to be received and may increase adverse effects, such as kidney damage.
As of the date of Amneal’s recall announcement, March 27, 2024, there have been no reports of adverse events related to this recall. To see if your medication was recalled, contact your doctor or pharmacy where you received the medication or visit the FDA website below.
If you have an affected lot of Vancomycin, you should stop using the item and return it to the place of purchase.
To learn more about this recall, you can take one or more of the steps below.
This drug is being recalled because some bottles may have been overfilled. This may cause a higher dose to be received and may increase adverse effects, such as kidney damage.
As of the date of Amneal’s recall announcement, March 27, 2024, there have been no reports of adverse events related to this recall. To see if your medication was recalled, contact your doctor or pharmacy where you received the medication or visit the FDA website below.
If you have an affected lot of Vancomycin, you should stop using the item and return it to the place of purchase.
To learn more about this recall, you can take one or more of the steps below.
- Talk to your doctor or pharmacist.
- Call Amneal at 1-833-582-0812. TTY users should call 711. Help is available Monday through Friday from 8 a.m. to 5 p.m. EST.
- Visit the FDA website.
Recent Announcements
The importance of PRD forms for complex patients and staying updated on changes
Personal representative designation (PRD) forms are critical to the care process for patients and providers alike. Not only do PRDs support accurate, efficient, and compliant patient care—they also streamline administrative processes.Aug. 2025Important Notices
Important announcement: UPMC Health Plan retires MP.PA.147
This communication is in regards to UPMC Health Plan Policy MP.PA.147 – Diagnostic and Surveillance Colonoscopy, 18 Years Old and Older. UPMC Health Plan previously communicated that the prior authorization requirement under this policy would be paused until Sept. 1, 2025. However, policy MP.PA.147 has been retired, and this policy will no longer be implemented or active.Aug. 2025Important Notices
CMS expands Medicare Advantage RADV audits to all eligible plans
On May 21, 2025, the Centers for Medicare & Medicaid Services (CMS) announced a substantial expansion of its Risk Adjustment Data Validation (RADV) audit program for Medicare Advantage plans.Aug. 2025What's New